|
Jun 12
|
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
|
|
Jun 12
|
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
|
|
Jun 11
|
Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials
|
|
Jun 11
|
Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 11
|
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
|
|
May 27
|
Merck Announces Third-Quarter 2025 Dividend
|
|
May 23
|
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
|
|
May 22
|
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
|
|
May 19
|
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|
|
May 19
|
The Top Corporate Board Directors
|
|
May 16
|
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
|
|
May 15
|
FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma
|
|
May 15
|
Jefferies not seeing significant impact to Merck, Bristol from draft guidance
|
|
May 15
|
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
|
|
May 14
|
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
|
|
May 14
|
Merck (NYSE:MRK) Showcases Broad Cancer Research Portfolio At ASCO Annual Meeting
|
|
May 13
|
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
|
|
May 12
|
Trump's drug price order is part request, part threat: Analyst
|
|
May 1
|
Top Dividend Stocks To Consider In May 2025
|